Acknowledgements & Contacts
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Independent Monitoring Board of the Global Polio Eradication Initiative Report
Independent Monitoring Board of the Global Polio Eradication Initiative Report July 2011 Independent This second report follows our third meeting, held in London on 30 June and 1 July 2011. Monitoring Board of the At present the needs are: Global Polio • To concisely understand the global situation Eradication Initiative • To maintain clear and energetic focus in each country with ongoing transmission July 2011 • To see the wood for the trees in identifying and dealing with the programme’s key risks • To find innovative solutions that break through entrenched problems • To surface fundamental problems that need urgent attention We are grateful to the many partners of the Global Polio Eradication Initiative who have provided us with information, logistical support, and valuable insights. We are grateful for their help, and commend their commitment. Our role remains to speak with a clear, objective voice that is independent of any of these partners. We each sit on this board in a personal capacity. We remain resolutely independent, and will continue to present our frank view without fear or favour. Sir Liam Donaldson (Chair) Dr Mushtaque Chowdhury* Former Chief Medical Officer, England Associate Director, Rockefeller Foundation Dr Nasr El Sayed Dr Ciro de Quadros Assistant Minister of Health, Egypt Executive Vice President, Sabin Vaccine Institute Dr Jeffrey Koplan Dr Sigrun Mogedal Vice President for Global Health Special Advisor, Norweigan Knowledge Centre Director, Emory Global Health Institute for the Health Services Professor Ruth Nduati Dr Arvind Singhal Chairperson, Department of Paediatrics and Child Health Marston Endowed Professor of Communication University of Nairobi University of Texas at El Paso Professor Michael Toole Head, Centre for International Health *Dr Chowdhury was unable to participate in the meeting but Burnet Institute, Melbourne endorses this report The Independent Monitoring Board was convened at the request of the World Health Assembly to monitor and guide the progress of the Global Polio Eradication Initiative’s 2010-12 Strategic Plan. -
THE ERADICATION of POLIOMYELITIS (Fhe Albert V.• Sabin Lecture)
THE ERADICATIONOF POLIOMYELITIS (fhe Albert V.•Sabin Lecture) by Donald Henderson, M.D., M.P.H. University Distinguished Service Professor The JohnsHopkins University Baltimore, Maryland 21205 Cirode Quadros, M.D., M.P.H. Regional Advisor Expanded Programme on lmmunii.ation Pan American Health Organization 525 23rd Street, N. W. Washington, D.C. 20037 Introduction The understanding and ultimate conquest of poliomyelitis was Albert Sabin's life long preoccupation, beginning with his earliest work in 1931. (Sabin and Olitsky, 1936; Sabin, 1965) The magnitude of that effort was aptly summarized by Paul in his landmark history of polio: "No man has ever contributed so much effective information - and so continuously over so many years - to so many aspects of poliomyelitis." (Paul, 1971) Thus, appropriately, this inaugural Sabin lecture deals with poliomyelitis and its eradication. Polio Vaccine Development and Its Introduction In the quest for polio control and ultimately eradication, several landmarks deserve special mention. At the outset, progress was contingent on the development of a vaccine and the production of a vaccine, in turn, necessitated the discovery of new methods to grow large quantities of virus. The breakthrough occurred in 1969 when Enders and his colleagues showed that large quantities of poliovirus could be grown in a variety of human cell tissue cultures and that the virus could be quantitatively assayed by its cytopathic effect. (Enders, Weller and Robbins, 1969) Preparation of an inactivated vaccine was, in principle, a comparatively straightforward process. In brief, large quantities of virus were grown. then purified, inactivated with formalin and bottled. Assurance that the virus had been inactivated could be demonstrated by growth in tissue. -
KDHE News Release
News Room - 2012 - News Release A to Z Topic Listing KDHE News Release For Immediate Release KDHE Office of Communications January 3, 2012 [email protected], 785-296-0461 KDHE Promotes Cancer Screenings and HPV Vaccination During Cervical Health Awareness Month TOPEKA – In recognition of Cervical Health Awareness Month, the Kansas Department of Health and Environment (KDHE) encourages women to schedule their annual well-woman checkups. According to a 2010 Kansas Behavioral Risk Factor Surveillance System (BRFSS) report, approximately 17 percent of Kansas women aged 18 and older did not have a Pap test within the past three years. "Pap tests decrease the risk of developing cervical cancer by detecting precancerous cells which, when found early, are highly treatable," said Robert Moser, M.D., KDHE Secretary and State Health Officer. “Women should have their first screening Pap test at age 21, or within three years of becoming sexually active if younger." Although cervical cancer was once the leading cancer killer of women, the number of cases has declined 75 percent in the past 50 years, largely because of the widely available and reliable Pap test. Even so, an estimated 12,000 women in the United States are diagnosed with cervical cancer each year. In 2007, 4,021 women died from cervical cancer in the United States. In 2008, 76 Kansas cases were diagnosed, with 24 deaths due to cervical cancer in 2010. Most cervical cancer cases are caused by infection with human papillomavirus (HPV), a common sexually transmitted disease. HPV infection can also cause a number of other health problems for both men and women. -
CV Seth Berkly2.Indd
Dr Seth Berkley Chief Executive Officer of the GAVI Alliance As a physician, epidemiologist and leading advocate for vaccines and immunisation, Dr Seth Berkley brings many years of experience and knowledge from the fields of public health, development and vaccines to the work of the Alliance. Seth joined the GAVI Alliance in August 2011 as it launched its five year strategy to immunise a quarter of a billion children in the developing world with life-saving vaccines by 2015. “I am impressed by GAVI’s life-saving work and have great admiration for its successful track record,” said Dr Berkley. “I am therefore honoured and excited to have been chosen to lead the GAVI Alliance as it works to deliver on an ambitious new strategy.” Prior to joining the GAVI Alliance, Seth was the founder, president and CEO for 15 years of the International AIDS Vaccine Initiative ( IAVI ), the first vaccine product development public-private sector partnership. Under his leadership, IAVI implemented a global advocacy programme that assured that vaccines received prominent attention in the media and in political forums such as the G 8, EU and the UN. He also oversaw the creation of a virtual vaccine product development effort involving industry, academia, and developing country scientists. Prior to founding IAVI, Seth served as associate director in the Health Sciences Division at The Rockefeller Foundation. He has also worked for the Center for Infectious Diseases of the U. S. Centers for Disease Control and Prevention ( CDC ), the Massachusetts Department of Public Health and for the Carter Center where he served as an epidemiologist at the Ministry of Health in Uganda. -
Fall 2011 MEDICINE
BROWN Volume 17 | Number 3 | Fall 2011 MEDICINE Gentleman Scholar Calm, cool, connected, Griffin Rodgers pushes for research that will serve the people. PS:l U PRIMARY CARE REIMAGINED MAKING BABIES c1BrMed_Spring11rev.indd 1 9/29/11 1:53 PM Letter from the dean Start of One Era, End of Another The opening of the new Medical School in Providence’s old Jewelry District on August 15 marked one of the most important mile- stones in our history. Now our students have a state-of-the-art, spacious, and absolutely stunning home to call their own. This his- toric, creatively restored building off Col- lege Hill is close to several of our major teaching hospitals and the Public Health Program. Furthermore, it symbolizes Brown’s commitment to the city and the state to educate the next generation of physicians for all of us. Reunion and Commencement were carried out with beautiful weather and our usual traditions. Alumnus Griffin P. Rodgers, director of the National Institute of Diabetes and Digestive and Kidney Diseases—one of the National Institutes of Health—gave an inspiring commencement speech to our graduating class and is featured in this issue. He emphasized the excitement of research in human biology in this era of genomics, proteomics, and systems biology. Advances over the next decades will be spectacular and will change the way we care for patients. Since the earliest classes, the Medical School’s graduates have enhanced the lives of their patients as well as their communities. Some, such as Dr. Rodgers, have gone on to national careers. -
Inaugural Keynote Lecture: Contributions of Gavi and DCVMN to the Global Vaccine Markets
Inaugural Keynote Lecture: Contributions of Gavi and DCVMN to the global vaccine markets DCVMN 18th AGM Seth Berkley M.D, CEO 26 September 2017, Seoul www.gavi.org Gavi’s mission, model and 1 achievements to date Gavi’s mission Saving by increasing and protecting in lower-income children’s equitable use of people’s health countries lives vaccines DCVMN 18th AGM 26 September 2017 Gavi’s partnership model IMPLEMENTING COUNTRY DONOR COUNTRY GOVERNMENTS GOVERNMENTS CIVIL SOCIETY RESEARCH & ORGANISATIONS TECHNICAL AGENCIES VACCINE PRIVATE MANUFACTURERS SECTOR PARTNERS DCVMN 18th AGM 26 September 2017 Increasing immunisation coverage Launch of Gavi Post-Gavi 20% increase points 2000-2016 1980 1985 1990 1995 2000 2005 2010 2016 2020 Expanded Programme Stall in immunisation Support from Gavi to world’s on Immunization takes off coverage lowest-income countries * Based on data officially reported to WHO and UNICEF by current member states. Note: Includes DTP-containing vaccines, such as pentavalent vaccine. th Source: WHO/UNICEF Estimates of National Immunization Coverage, 2017 DCVMN 18 AGM 26 September 2017 Accelerating access to new vaccines in poorest countries Prior to Gavi support Now High-income countries Low-income countries High-income countries Low-income countries 100% 100% 100% 91% 86% 86% 77% 72% Hepatitis B 67% Hib Pneumococcal % of countries introduced vaccines nationally 3% 6% 6% 2000 2009 2000 2009 2016 Note: Only countries with universal national introduction are included. World Bank 2016 country classification has been applied to the whole time series. DCVMN 18th AGM Source: The International Vaccine Access Center (IVAC) VIMS database. Data as of 31 December 2016. -
Leadership in Global Health: the Case of Ciro De Quadros, a Testament to Values, Valor, and Vision
Pan American Journal Profile of Public Health When Dr. Bill Foege wrote “When Words Fail,” he was referring to how difficult Leadership in it was for him to describe adequately, in written words, all the effort that is involved from the scientific conceptualization of a new vaccine, to eventual bench discovery global health: and development, to the training and supply chain logistics, and ultimately to the moment the needle pricks the skin to save a life of a child (1). He called it the “chain the case of Ciro of perfection”. He was “at a loss” to describe this cascade of events with due justice. I have been asked to describe the leadership attributes of Dr. Ciro de Quadros as a de Quadros, a case study in best practice and lessons to be learned. Similarly, I too am at a loss. Simply put, Ciro broke the mold. testament to I should disclose that what I am about to write is influenced by decades of either working directly for Ciro, as was the case during the polio eradication era in the Americas, to collaborating with Ciro more recently on various projects that in- values, valor, cluded measles and rubella elimination, the introduction of new vaccines, and sur- veillance of infectious diseases. The work evolved into a relationship that bridged and vision from professional mentorship, to actual friends with a deep sense of admiration, love, and mutual respect. In global health, leadership is somewhat like the “self-actualization” of public Jon Kim Andrus1 health practice. The “leader” must have all those attributes that embodies a fully realized individual, positioned in the system to make things happen, such as in Ciro’s case, to help create a world of equitable access to life-saving vaccines. -
Seth Berkley MD
Seth Berkley M.D. Chief Executive Officer of the GAVI Alliance Seth Berkley joined the GAVI Alliance as CEO in August 2011, as it launched its five year strategy to immunise a quarter of a billion children in the developing world with life-saving vaccines by 2015. Prior to joining the GAVI Alliance, Seth was the founder, president and CEO for 15 years of the International AIDS Vaccine Initiative ( IAVI ), the first vaccine product development public-private sector partnership. Under his leadership, IAVI implemented a global advocacy programme that assured that vaccines received prominent attention in the media and in forums such as the G 8, EU and the UN. He also oversaw the creation of a virtual vaccine product development effort involving industry, academia, and developing country scientists. Prior to founding IAVI, Seth served as associate director in the Health Sciences Division at The Rockefeller Foundation. He has also worked for the Center for Infectious Diseases of the U. S. Centers for Disease Control and Prevention ( CDC ), the Massachusetts Department of Public Health and for the Carter Center where he served as an epidemiologist at the Ministry of Health in Uganda. He has consulted or worked in more than 25 countries in Asia, Africa and Latin America. Seth sits on a number of international steering committees and corporate and not-for-profit boards, including those of Gilead Sciences, the New York Academy of Sciences and the Acumen Fund. In the past, he has also served on the boards of public and private vaccine companies such as PowderJect and VaxInnate and health and development organisations such as OXFAM America. -
COVID-19 Vaccine Development, Strategy and Implementation
Symposium: Vaccines and Global Health: COVID-19 Vaccine Development, Strategy and Implementation The Program in Vaccine Education at the Columbia University Vagelos College of Physicians & Surgeons’ mission is to educate medical students and to inform health care professionals, public health experts, academic, government and industry researchers, policy makers, global health non-governmental organizations, journalists, and the general public as to the cutting-edge advances and challenges in modern vaccine development. The Columbia University convenors are Drs. Lawrence Stanberry (Co-Director, PVE), Philip LaRussa (Co-Director, PVE), Wilmot James (Associate Director, PVE), and Marc Grodman (Special Advisor, PVE). We have put together a group of 25 outstanding speakers who have been intimately involved with all aspects of COVID-19 vaccine development, strategy, and implementation. We are delighted to present this five-day virtual symposium at the cusp of the world’s transition to controlling the COVID-19 pandemic. Monday, February 22 National, Regional and Global Response to an Unprecedented Challenge 12:00-12:10 Welcome: Lee Bollinger, JD – President, Columbia University 12:10-12:15 Moderator: Lawrence R. Stanberry, MD, PhD – Director of the Programs in Global Health, Columbia University Vagelos College of Physicians and Surgeons 12:15-12:45 Keynote: Sir Jeremy Farrar, BSc, MBBS, PhD – Director, Wellcome Trust The Role of the Wellcome Trust in COVID-19 Vaccine Preparedness 12:45-1:30 Speakers: - Shabir Madhi, MBChB, MMed, FCPaeds PhD – Professor of Vaccinology, University of the Witwatersrand – A South African perspective on vaccine preparedness and availability. - Nancy Messonnier, MD – Director, National Center for Immunization and Respiratory Diseases, US CDC – A US CDC perspective on vaccine preparedness and availability. -
2021 GTFCC World Health Assembly Side Event 20 May 2021 Biographies: Speakers and Moderators
2021 GTFCC World Health Assembly Side Event 20 May 2021 Biographies: Speakers and Moderators 1 Biographies: Table of Contents Dr. Tedros Adhanom Ghebreyesus..................................................................................... 3 Dr. Frew Benson ............................................................................................................... 4 Dr. Seth Berkley ............................................................................................................... 5 Dr. Christopher R. Braden.................................................................................................. 6 Dr. Godfrey Bwire ............................................................................................................. 7 Mr. Emanuele Capobianco ................................................................................................ 8 Ms. Simone Carter ............................................................................................................ 9 Mr. Wiseman Chimwaza ................................................................................................. 10 Ms. Pamela Mwelala Chisanga ....................................................................................... 11 Dr. Marc Gastellu-Etchegorry .......................................................................................... 12 Christine Marie George, PhD ........................................................................................... 13 Dr. Myriam Henkens ...................................................................................................... -
2010 Albert B. Sabin Gold Medal Awarded to Dr. John D. Clemens
Home About Us Press Room Support Sabin Michael Marine May 2010 Appointed CEO of The Sabin Report | Volume 12 Issue 2 Sabin Vaccine Institute 2010 Albert B. Sabin Gold Medal Awarded to Dr. John D. Clemens During a ceremony at The George Washington University City View Room, Dr. John D. Clemens, Director General of the International Vaccine Institute in Seoul, Korea, received the 2010 Albert B. Sabin Gold Medal Award for his contributions to reducing suffering and promoting peace Dr. Steven Knapp, The George Washington through the development, University President; Dr. John D. Clemens; evaluation, and distribution of and Dr. Peter Hotez, Sabin President and Michael W. Marine, former The George Washington University vaccines. Distinguished Research Professor US Ambassador to the Socialist Republic of Dr. Clemens led the first efficacy trial of an oral vaccine against Vietnam, was appointed as cholera, and conducted additional research on a measles vaccine as the new chief executive a research scientist at the International Center for Diarrhoeal Disease officer of the Sabin Research, Bangladesh during the 1980s. IVI scientists transferred Vaccine Institute on April the technology for the cholera vaccine to Shantha Biotechics of 28, announced Sabin's Hyderabad, India, and in 2009, Shanchol™ was licensed for Chairman of the Board of development. Trustees, Mort Hyman and President Dr. Peter Hotez. Through his stewardship at the International Vaccine Institute in Seoul, Korea where he has served as Director General since 1999, Marine joined Sabin's Dr. Clemens has engaged in vaccine diplomacy in many areas, leadership team in including the Democratic People's Republic of Korea Program, which December 2009 after aims to reduce the disease burden of Hib and Japanese encephalitis serving eight months on in North Korean children by providing technical assistance in the Joint Action Committee laboratory diagnosis and surveillance of these diseases and in the of the Global Network for introduction of vaccines to prevent them. -
(GIN) Global Immunization News
Global Immunization News (GIN) Global Immunization News (GIN) May 2019 In this issue News You can click on the article 72nd World Health Assembly Special Report you are interested in and ac- Hayatee Hasan, WHO Headquarters cess it directly! This year’s World Health Assembly was held from 20 News to 28 May 2019 at the Palais des Nations in Geneva, • Immunization Agenda 2030 2 Switzerland and was attended by nearly 4000 delegates • Advancing digital health in 2 from WHO’s 194 Member States and partner organiza- Bangladesh through electron- ic immunization registration tions. The general theme of this year’s World Health • The world’s first malaria 3 Assembly (WHA) was "Universal health coverage: leav- vaccine highlighted at ing no-one behind”. #WHA72 The Assembly Hall at the Palais des Nations 3 in Geneva, Switzerland. • Malaria vaccine pilot Key highlights included: launched in Ghana • WHO announced the appointment of four new goodwill ambassadors from the fields of sports, • Over 100 000 people sick 3 with measles in 14 months: politics and community mobilization to promote healthier lives, stronger health workforces and with measles cases at an improved mental health globally. The new ambassadors are: alarming level in the Europe- 1. Alisson Becker, goalkeeper of the Brazilian national and Liverpool football teams; an Region, WHO scales up 2. Dr Natália Loewe Becker, medical doctor and health advocate from Brazil, as WHO response Goodwill Ambassadors for Health Promotion; • WHO adapts ebola vaccina- 4 tion strategy in the Demo- 3. Cynthia Germanotta, President of Born This Way Foundation, which was co-founded cratic Republic of the Congo with her daughter Lady Gaga, as WHO Goodwill Ambassador for Mental Health; and to account for insecurity and 4.